Biologics to Play Leading Role in McKesson’s Strategy

McKesson Corporation announced a multi-year strategic growth initiative in 2018, focused on creating innovative new solutions that improve patient care delivery and drive incremental profit growth.

The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure, designed to increase efficiency, accelerate execution and improve long-term performance.

McKesson’s growth priorities include expanded supply chain and commercialization services for pharmaceutical and medical supply manufacturers; enhanced solutions for the rapidly-growing specialty pharmaceutical market, and; new offerings that will strengthen and expand the role of retail pharmacy in patient care delivery.

McKesson expects investments in these areas will accelerate the company’s growth trajectory over the long term. Continuing to implement this strategy, independent specialty pharmacy Biologics by McKesson has recently reached a number of agreements to expand its offerings.

Biologics by McKesson is an independent specialty pharmacy with over 24 years of experience connecting patients to life-changing medications in oncology and other complex therapeutic areas.

Sanofi Genzyme selected Biologics as the exclusive specialty pharmacy provider of its Cablivi. Cablivi was recently approved by the FDA for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura, a rare, life-threatening blood-clotting disorder. This agreement expands Biologics offering to its specialty pharmacy solutions for patients with complex conditions beyond oncology.

Biologics has also been selected by Astellas Pharma US to be in the limited distribution network for XOSPATA^®(gilteritinib).